D. Watson

发表

A Genome-Wide Association Study Identifies Novel Loci for Paclitaxel-Induced Sensory Peripheral Neuropathy in CALGB 40101

Yusuke Nakamura, Chen Jiang, Howard L. McLeod, 2012, Clinical Cancer Research.

Comparison of performance status with peak oxygen consumption in operable patients with non‐small‐cell lung cancer

L. Jones, W. Hornsby, N. Eves, 2014, Respirology.

Preoperative Exercise Vo2 Measurement for Lung Resection Candidates: Results of Cancer and Leukemia Group B Protocol 9238

Kemp Kernstine, Dorothy Watson, D. Sugarbaker, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Induction chemotherapy followed by concomitant chemoradiotherapy (CT/XRT) versus CT/XRT alone for regionally advanced unresectable non-small cell lung cancer (NSCLC): Initial analysis of a randomized phase III trial.

J. Herndon, E. Vokes, M. Kelley, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Medulloblastoma and Birth Date: Evaluation of 3 U.S. Datasets

S. George, M. Miranda, E. Halperin, 2004, Archives of environmental health.

Interruptions of once-daily thoracic radiotherapy do not correlate with outcomes in limited stage small cell lung cancer: analysis of CALGB phase III trial 9235.

J. Herndon, E. Vokes, Mark R. Green, 2008, Lung cancer.

Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B.

J. Herndon, E. Vokes, M. Kelley, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Single-agent versus combination chemotherapy in advanced non-small cell lung cancer (NSCLC): A CALGB randomized trial of efficacy, quality of life, and cost-effectiveness

C. Desch, J. Herndon, Mark R. Green, 2001 .

Lack of trastuzumab activity in nonsmall cell lung carcinoma with overexpression of erb‐B2

R. Govindan, J. Herndon, Mark R. Green, 2005, Cancer.

A phase II study of carboplatin, etoposide and exisulind in patients with extensive stage small cell lung cancer: CALGB 30104

Michael R. Green, R. Govindan, J. Herndon, 2005 .

70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited-stage small-cell lung cancer: analysis of Cancer and Leukemia Group B study 39808.

J. Herndon, A. Turrisi, Mark R. Green, 2004, International journal of radiation oncology, biology, physics.

CALGB 140803-Association between cardiorespiratory fitness and overall survival in operable lung cancer patients: Ancillary analysis of protocol 9238.

J. Herndon, L. Jones, N. Eves, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Duration of symptoms prior to diagnosis is related inversely to presenting disease stage in children with medulloblastoma

S. George, E. Halperin, D. Watson, 2001, Cancer.

Novel doublets in extensive-stage small-cell lung cancer: a randomized phase II study of topotecan plus cisplatin or paclitaxel (CALGB 9430).

T. Lynch, J. Herndon, A. Turrisi, 2002, Clinical lung cancer.

Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups.

David J Sugarbaker, Richard L Schilsky, R. Schilsky, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II trial of 6-hydroxymethylacylfulvene (MGI-114, irofulven) in patients with relapsed or refractory non-small cell lung cancer.

J. Herndon, Mark R. Green, D. Watson, 2004, Lung cancer.

Randomized Clinical Trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in Stage IB Non-Small Cell Lung Cancer (NSCLC): Report of Cancer and Leukemia Group B (CALGB) Protocol 9633.

R. Schilsky, D. Sugarbaker, J. Herndon, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gefitinib in Patients with Malignant Mesothelioma: A Phase II Study by the Cancer and Leukemia Group B

R. Govindan, J. Herndon, R. Kratzke, 2005, Clinical Cancer Research.

O-277 CALGB 9732: Final report of a randomized phase III intergroup trial of etoposide(VP-16) and cisplatin (DDP) with or without paclitaxel(TAX) and G-CSF in patients with extensive stage small cell lung cancer(ED-SCLC)

Michael R. Green, R. Marks, K. Kelly, 2003 .

Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901

M. Socinski, J. Herndon, E. Vokes, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Integration of Cell Line and Clinical Trial Genome-Wide Analyses Supports a Polygenic Architecture of Paclitaxel-Induced Sensory Peripheral Neuropathy

Ivo D. Shterev, E. Winer, Yusuke Nakamura, 2012, Clinical Cancer Research.

Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203.

Carl Morrison, S. Jewell, C. Morrison, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

An initial genetic analysis of gemcitabine-induced high-grade neutropenia in pancreatic cancer patients in CALGB 80303 (Alliance)

Y. Furukawa, K. Owzar, M. Ratain, 2019, Pharmacogenetics and genomics.

Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730).

J. Holland, C. Desch, J. Herndon, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation: results of CALGB Study 10001 (Alliance)

C. Bloomfield, R. Larson, W. Stock, 2014, Haematologica.

Capecitabine in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (39807).

J. Herndon, Mark R. Green, G. Otterson, 2001, Lung cancer.

A Phase III Trial Evaluating the Combination of Cisplatin, Etoposide, and Radiation Therapy With or Without Tamoxifen in Patients With Limited-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study (9235)

J. Herndon, Mark R. Green, J. Bogart, 2005, American journal of clinical oncology.

Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): Update of Cancer and Leukemia Group B (CALGB) protocol 9633.

D. Sugarbaker, J. Herndon, E. Vokes, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732.

R. Marks, K. Kelly, J. Herndon, 2005, Journal of Clinical Oncology.

Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy

Ivo D. Shterev, P. Febbo, Yusuke Nakamura, 2016, Clinical Cancer Research.

Peak oxygen consumption and long‐term all‐cause mortality in nonsmall cell lung cancer

J. Herndon, D. Watson, G. Loewen, 2010, Cancer.

Autologous Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Achieves Outcomes Similar to Allogeneic Transplantation - Results of CALGB 10001 (Alliance)

C. Bloomfield, K. Owzar, R. Larson, 2012 .

Participation in Cancer Pharmacogenomic Studies: A Study of 8456 Patients Registered to Clinical Trials in the Cancer and Leukemia Group B (Alliance).

K. Owzar, M. Ratain, P. Friedman, 2015, Journal of the National Cancer Institute.

Phase II trial of paclitaxel-topotecan-etoposide (PTE) followed by consolidation chemoradiotherapy for limited stage small cell lung cancer (LS-SCLC): CALGB 30002

Michael R. Green, E. Vokes, J. Bogart, 2005 .

Abl Kinase Domain Mutations Leading to Relapse of Ph+ Acute Lymphoblastic Leukemia (ALL) Occur Commonly and Can Be Detected At Initial Diagnosis: Molecular Results From CALGB 10001

C. Bloomfield, K. Owzar, R. Larson, 2011 .

A pharmacogenetic study of aldehyde oxidase I in patients treated with XK469.

E. Gamazon, K. Owzar, M. Ratain, 2014, Pharmacogenetics and genomics.

Peak oxygen consumption and long‐term all‐cause mortality in nonsmall cell lung cancer

J. Herndon, D. Watson, G. Loewen, 2010, Cancer.

Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203.

S. Jewell, C. Morrison, M. Edelman, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Eicosanoid modulation in advanced non-small cell lung cancer (NSCLC): CALGB 30203.

M. Edelman, E. Vokes, R. Kratzke, 2006, Journal of Clinical Oncology.